Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors

BACKGROUND: ICIs have remarkably affected the treatment strategies for numerous malignancies, including lung cancer. However, only a fraction of patients experience durable responses to ICIs; thus, there is an urgent need to identify the parameters related to ICI therapeutic effects. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhenzhen, Diao, Yuzhu, Li, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336031/
https://www.ncbi.nlm.nih.gov/pubmed/35902908
http://dx.doi.org/10.1186/s12885-022-09744-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336031/
https://www.ncbi.nlm.nih.gov/pubmed/35902908
http://dx.doi.org/10.1186/s12885-022-09744-5

Ejemplares similares